Menopause and Cellular Aging

What research reveals about hormone changes and the health of our cells.

BY RESETTA EDITORIAL

A night interrupted by heat. Less energy for a familiar workout. A growing concern about muscle or bone health. During the menopause transition, these changes can prompt a larger question: what is happening beneath the symptoms?

Research offers part of an answer. Changes in ovarian hormones can affect cellular processes, and some health interventions improve specific functions in postmenopausal women. But the evidence does not establish a single chain in which menopause accelerates every aspect of cellular aging and an anti-aging treatment reverses the consequences. The findings depend on the tissue, the intervention, and what researchers actually measured. [1–9]

Understanding those distinctions makes the science more useful. It helps explain why sleep, physical activity, and appropriate menopause care deserve attention, while keeping emerging longevity treatments in perspective.

What Cellular Aging Means in This Discussion

Several different biological processes appear under the label of cellular aging. Mitochondria help cells produce usable energy. Mitophagy is a quality-control process that removes damaged mitochondria. Cellular senescence describes a state in which cells stop dividing and can release signals that affect nearby tissue, including inflammatory signals. Senescence also has protective functions, so eliminating it indiscriminately is not the goal. [3–5]

Biological-age estimates are different again. An epigenetic clock calculates an age-related pattern from chemical marks on DNA. It does not directly count senescent cells or measure how well a muscle produces energy. A change in one of these measurements cannot automatically stand in for a change in all the others. [2]

This matters when reading a headline. A study reporting a blood biomarker has answered a narrower question than a study showing fewer fractures, better physical function, or longer life.

The Connection Begins Before the Final Menstrual Period

Cellular maintenance can help shape reproductive aging itself. In a 2021 Nature study, Ruth and colleagues examined genetic variation in roughly 200,000 women of European ancestry and identified 290 genetic determinants associated with the timing of natural menopause. Their analyses highlighted pathways involved in the response to DNA damage. [1]

This places ovarian aging within a broader biological context: how cells respond to damage can influence reproductive lifespan. It also complicates the idea that menopause simply starts an otherwise unrelated aging process. Shared biology may contribute to both. Genetic associations and accompanying experimental work do not, however, show that a supplement can preserve human ovarian function or safely delay menopause. [1]

A separate 2016 PNAS study by Levine and colleagues analyzed epigenetic age across four observational cohorts. Earlier menopause and a longer time since menopause were associated with greater epigenetic age acceleration in blood; bilateral ovary removal was also associated with this measure. [2]

These findings support a connection between reproductive history and biological-age markers. They do not fully resolve its direction. Hormonal changes may contribute, while shared genetics, health exposures, and other differences may also influence both menopause timing and aging. An epigenetic association is not proof that menopause makes every organ age at a uniform rate. [2]

A Muscle Study Identifies a Possible Causal Pathway

A study by Uebo and colleagues, published online in November 2025 and in the January 2026 issue of Experimental Gerontology, examined estrogen deficiency in mice and cultured human skeletal muscle cells. These were laboratory models, not a clinical trial in menopausal women. [3]

In the cultured cells, estrogen-deficient conditions reduced mitophagy and expression of Rab9, a protein involved in an alternative cellular recycling pathway. Mitochondrial function and muscle-cell differentiation deteriorated, while senescence increased. Experimentally increasing Rab9 improved these outcomes. [3]

Because the researchers altered the pathway and observed a rescue, this is stronger mechanistic evidence than a simple correlation. It suggests that impaired mitochondrial maintenance can help connect estrogen deficiency with muscle dysfunction in these models. The study also tested NMN in mice, but neither that result nor the cell experiment demonstrates that NMN prevents muscle loss in menopausal women. [3]

Bone Research Shows Why the Pathway Is Not Universal

A 2019 study by Farr and colleagues reached a different conclusion in bone. In young adult mice, removal of the ovaries caused bone loss without increasing the measured senescence markers. A strategy designed to eliminate certain senescent cells did not prevent that estrogen-deficiency-related bone loss. [4]

The researchers also examined bone biopsies from older postmenopausal women. Three weeks of estrogen treatment in 10 women, compared with 10 untreated women, did not alter the measured senescence markers or senescence-associated secretory signals. [4]

The small sample and brief treatment period limit what can be concluded. Even so, the results challenge a universal sequence of estrogen loss, senescent-cell accumulation, and tissue damage. In these experiments, estrogen deficiency and cellular senescence acted through separable routes. Menopause care and treatments aimed at senescent cells therefore cannot be assumed to be interchangeable. [4]

Hormone Therapy Can Influence Some Biomarkers

Human intervention evidence adds another layer. A 2020 analysis of 109 participants in the randomized Kronos Early Estrogen Prevention Study compared blood proteins after 36 months of oral conjugated estrogens, transdermal estradiol, or placebo. The proteins were associated with senescence and inflammation. [5]

The oral-estrogen group had lower levels of several measured proteins than placebo. Results were less consistent for transdermal estradiol, and one marker, MIP1α, showed no significant treatment effect. These findings support an effect of the assigned treatment on selected circulating markers, with differences between regimens. [5]

Blood proteins are not a direct census of senescent cells. The analysis did not demonstrate whole-body rejuvenation or establish that changing these markers prevents age-related disease. [5]

Hormone therapy has established uses for bothersome menopause symptoms and can protect against bone loss. Whether it is appropriate depends on individual symptoms, medical history, age, timing, and treatment formulation. A discussion with a clinician should focus on those benefits and risks; the biomarker study alone is not a reason to start hormone therapy for anti-aging. [10]

Health Management Can Change Specific Cellular and Metabolic Functions

The practical question is whether women can influence functions that matter during and after this transition. Exercise and sleep studies provide useful evidence, even though neither establishes reversal of cellular aging.

Aerobic Training in Early Postmenopause

In a 2017 study in The Journal of Physiology, 20 premenopausal and 16 recently postmenopausal women completed 12 weeks of aerobic training at high intensity. Researchers observed vascular and skeletal-muscle mitochondrial adaptations, including increases in several mitochondrial respiratory-chain proteins in the postmenopausal group. Some adaptations were greater in that group. [6]

The study was small, compared groups before and after training, and did not include an inactive control group. It nevertheless shows that muscle remains responsive to training in early postmenopause. It does not establish a reversal of biological age or mean that everyone should begin with high-intensity exercise. [6]

Sleep Restriction and Insulin Sensitivity

Sleep has also been tested experimentally. In a 2023 randomized crossover trial, Singh and colleagues compared habitual sleep with four nights of restricted sleep in postmenopausal women. Fourteen entered the trial and nine were included in the reported analysis. Time in bed averaged approximately 8.4 hours during habitual sleep and 5.0 hours during restriction. [7]

Insulin sensitivity declined during sleep restriction. Because the same women experienced both conditions in randomized order, this supports a short-term causal effect of insufficient sleep on metabolic function in this small sample. The trial did not measure senescent-cell burden or demonstrate that improving sleep reverses aging. It gives a concrete reason to take persistent sleep disruption seriously. [7]

Emerging Longevity Interventions Have Narrower Evidence

Research on cellular pathways naturally raises interest in supplements and senolytics, treatments intended to selectively eliminate senescent cells. Human results require close attention to the population and the endpoint.

NMN in a Metabolic Trial

In a 2021 randomized, double-blind trial published in Science, 25 postmenopausal women with prediabetes and overweight or obesity received NMN or placebo for 10 weeks. The NMN group received 250 mg daily and showed improvement in muscle insulin sensitivity. [8]

That is a specific metabolic finding in a selected population. It does not establish relief of hot flashes, treatment of diabetes, delayed menopause, or reversal of cellular aging. The study regimen is a research detail, not a dosing recommendation. [8]

A Senolytic Trial in Bone

A 2024 phase 2 randomized trial in Nature Medicine tested intermittent dasatinib plus quercetin in 60 postmenopausal women. The trial did not meet its primary endpoint: the change in a blood marker of bone resorption at 20 weeks was not significantly different from control. An early improvement in a bone-formation marker was not sustained at 20 weeks. [9]

Exploratory findings suggested that women with higher baseline levels of a senescence-associated marker might respond differently. That is a question for further trials, not proof of broad benefit. The combination included a prescription drug; its results cannot be transferred to quercetin alone or to other marketed longevity supplements. [9]

Putting the Findings Into Everyday Care

A useful plan begins with observable health needs. Discuss persistent sleep disruption and troublesome menopause symptoms with a clinician. Build regular aerobic and muscle-strengthening activity at a level suited to your health and current ability. Review bone health, blood pressure, and other relevant risk factors during routine care. Adequate nutrition, including calcium and vitamin D, belongs in that discussion. These are established health priorities; the studies above do not establish them as a unified treatment that slows whole-body cellular aging. [10,11]

Most of the intervention studies described here enrolled women after menopause. Their results should not automatically be applied to all women in perimenopause, whose hormonal patterns and symptoms can differ.

References

Primary research is listed in references 1 to 9. References 10 and 11 provide clinical and patient education context.

1. Ruth KS et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature. 2021;596:393–397. doi.org/10.1038/s41586-021-03779-7
2. Levine ME et al. Menopause accelerates biological aging. Proceedings of the National Academy of Sciences. 2016;113(33):9327–9332. doi.org/10.1073/pnas.1604558113
3. Uebo S et al. Disruption of Rab9-dependent mitophagy contributes to menopause-induced sarcopenia. Experimental Gerontology. 2026;213:112970. Published online November 20, 2025. doi.org/10.1016/j.exger.2025.112970
4. Farr JN et al. Independent Roles of Estrogen Deficiency and Cellular Senescence in the Pathogenesis of Osteoporosis: Evidence in Young Adult Mice and Older Humans. Journal of Bone and Mineral Research. 2019;34(8):1407–1418. doi.org/10.1002/jbmr.3729
5. Faubion L et al. Effect of menopausal hormone therapy on proteins associated with senescence and inflammation. Physiological Reports. 2020;8(16):e14535. doi.org/10.14814/phy2.14535
6. Nyberg M et al. Leg vascular and skeletal muscle mitochondrial adaptations to aerobic high-intensity exercise training are enhanced in the early postmenopausal phase. The Journal of Physiology. 2017;595(9):2969–2983. doi.org/10.1113/JP273871
7. Singh P et al. Effect of sleep restriction on insulin sensitivity and energy metabolism in postmenopausal women: A randomized crossover trial. Obesity. 2023;31(5):1204–1215. doi.org/10.1002/oby.23739
8. Yoshino M et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224–1229. doi.org/10.1126/science.abe9985
9. Farr JN et al. Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nature Medicine. 2024;30:2605–2612. doi.org/10.1038/s41591-024-03096-2
10. The Menopause Society. Hormone Therapy. Patient education. Accessed October 22, 2026. menopause.org
11. National Institutes of Health. Menopause. Patient education. Accessed October 22, 2026. health.nih.gov